
Quarterly report 2024-Q3
added 05-23-2026
Acutus Medical Revenue 2011-2026 | AFIB
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Acutus Medical
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.2 M | 7.16 M | 3.03 M | 17.3 M | 8.46 M | 2.84 M | 2.17 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.2 M | 2.17 M | 8.73 M |
Quarterly Revenue Acutus Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.27 M | 4.13 M | 3.62 M | - | 5.24 M | 5.29 M | 4.17 M | - | 3.64 M | 4.08 M | 3.68 M | - | 4.6 M | 4.71 M | 3.59 M | - | 3.17 M | 1.13 M | 1.58 M | - | 646 K | 734 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.29 M | 646 K | 3.49 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
EDAP TMS S.A.
EDAP
|
64.1 M | $ 4.3 | -0.69 % | $ 161 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
366 M | - | - | $ 3.31 B | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Helius Medical Technologies
HSDT
|
6.02 M | $ 2.29 | -2.97 % | $ 50.5 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 11.44 | -2.22 % | $ 324 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 8.27 | 0.49 % | $ 1.24 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.01 | - | $ 17.1 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 73.83 | 0.26 % | $ 4.03 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 6.09 | 2.35 % | $ 72.8 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.46 | 0.17 % | $ 28.6 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 18.37 | -0.33 % | $ 431 M | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.55 | 0.65 % | $ 63.1 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 11.02 | -3.76 % | $ 395 M | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.62 | 0.28 % | $ 535 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Myomo
MYO
|
40.9 M | $ 1.04 | 9.47 % | $ 43.5 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 10.75 | 3.27 % | $ 426 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
64 M | $ 38.22 | -0.93 % | $ 323 M | ||
|
Butterfly Network
BFLY
|
97.6 M | $ 4.47 | -0.22 % | $ 1.1 B | ||
|
Profound Medical Corp.
PROF
|
16.1 M | $ 6.83 | -2.01 % | $ 206 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 84.81 | 0.24 % | $ 11.5 B | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.39 | 3.91 % | $ 6.63 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 154.87 | -1.29 % | $ 10.9 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 37.23 | 0.57 % | $ 1.16 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 43.84 | -2.01 % | $ 1.29 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 89.28 | -0.8 % | $ 3.1 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 85.78 | 3.1 % | $ 50.2 B | ||
|
TransMedics Group
TMDX
|
605 M | $ 68.94 | 0.12 % | $ 2.34 B |